Agenda of the PRAC meeting 9-12 March 2026
Submitted by Anonymous (not verified) on 9 March 2026 - 13:50
Agenda of the PRAC meeting 9-12 March 2026
EMEA-003502-PIP02-24
Submitted by Anonymous (not verified) on 9 March 2026 - 13:47
EMEA-003502-PIP02-24
PRAC recommendations on signals adopted at the 9-12 February 2026 PRAC meeting
Submitted by Anonymous (not verified) on 9 March 2026 - 13:45
PRAC recommendations on signals adopted at the 9-12 February 2026 PRAC meeting
List of signals discussed at PRAC since September 2012
Submitted by Anonymous (not verified) on 9 March 2026 - 13:44
List of signals discussed at PRAC since September 2012
EMA/PE/0000243095
Submitted by Anonymous (not verified) on 9 March 2026 - 10:39
EMA/PE/0000243095
Opinion/decision on a Paediatric investigation plan (PIP): Omvoh, mirikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: EMA/PE/0000232930
Submitted by Anonymous (not verified) on 9 March 2026 - 10:35
Opinion/decision on a Paediatric investigation plan (PIP): Omvoh, mirikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: EMA/PE/0000232930
Opinion/decision on a Paediatric investigation plan (PIP): Omvoh, mirikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: EMA/PE/0000232848
Submitted by Anonymous (not verified) on 9 March 2026 - 10:34
Opinion/decision on a Paediatric investigation plan (PIP): Omvoh, mirikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: EMA/PE/0000232848
National Innovation Offices Contacts
Submitted by Anonymous (not verified) on 9 March 2026 - 10:11
National Innovation Offices Contacts
Organisation Management Service (OMS)
Submitted by Anonymous (not verified) on 9 March 2026 - 8:29
Organisation Management Service (OMS)
Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz, tofacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: EMA/PE/000022
Submitted by Anonymous (not verified) on 6 March 2026 - 15:08
Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz, tofacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: EMA/PE/0000222532